Database

Startups

Main Industry
Health Care
Main Product/Service
AngenMed’s core offering is based on its proprietary ANG‑NeoSync® platform, which identifies patient‑specific tumor neoantigens to develop mRNA vaccines and cultivates antigen‑specific dendritic cells (DC) and T cells (NeoPrime® DC / NeoBoost® T‑cells) —
Founded Year
2024
Unified Business No.
96790452
Status
Active
Number of Employees
0
Total Paid-in Capital
500,000 (NT$)
Location of Company
Taiwan , Taichung City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you. Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
About the Company
AngenMed Therapeutics INC. is a Taiwanese biotech company focused on precision immunocellular therapies, aiming to bridge cutting‑edge research and clinical application so as to combat cancer and offer new hope to patients.



More ↓

Similar Companies